These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16302794)

  • 1. Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K.
    Palmer JT; Bryant C; Wang DX; Davis DE; Setti EL; Rydzewski RM; Venkatraman S; Tian ZQ; Burrill LC; Mendonca RV; Springman E; McCarter J; Chung T; Cheung H; Janc JW; McGrath M; Somoza JR; Enriquez P; Yu ZW; Strickley RM; Liu L; Venuti MC; Percival MD; Falgueyret JP; Prasit P; Oballa R; Riendeau D; Young RN; Wesolowski G; Rodan SB; Johnson C; Kimmel DB; Rodan G
    J Med Chem; 2005 Dec; 48(24):7520-34. PubMed ID: 16302794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel class of nonpeptidic biaryl inhibitors of human cathepsin K.
    Robichaud J; Oballa R; Prasit P; Falgueyret JP; Percival MD; Wesolowski G; Rodan SB; Kimmel D; Johnson C; Bryant C; Venkatraman S; Setti E; Mendonca R; Palmer JT
    J Med Chem; 2003 Aug; 46(17):3709-27. PubMed ID: 12904076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
    Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
    J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys.
    Kumar S; Dare L; Vasko-Moser JA; James IE; Blake SM; Rickard DJ; Hwang SM; Tomaszek T; Yamashita DS; Marquis RW; Oh H; Jeong JU; Veber DF; Gowen M; Lark MW; Stroup G
    Bone; 2007 Jan; 40(1):122-31. PubMed ID: 16962401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The consequences of lysosomotropism on the design of selective cathepsin K inhibitors.
    Black WC; Percival MD
    Chembiochem; 2006 Oct; 7(10):1525-35. PubMed ID: 16921579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L.
    Falgueyret JP; Oballa RM; Okamoto O; Wesolowski G; Aubin Y; Rydzewski RM; Prasit P; Riendeau D; Rodan SB; Percival MD
    J Med Chem; 2001 Jan; 44(1):94-104. PubMed ID: 11141092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats.
    Kim MK; Kim HD; Park JH; Lim JI; Yang JS; Kwak WY; Sung SY; Kim HJ; Kim SH; Lee CH; Shim JY; Bae MH; Shin YA; Huh Y; Han TD; Chong W; Choi H; Ahn BN; Yang SO; Son MH
    J Pharmacol Exp Ther; 2006 Aug; 318(2):555-62. PubMed ID: 16699068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.
    Stroup GB; Lark MW; Veber DF; Bhattacharyya A; Blake S; Dare LC; Erhard KF; Hoffman SJ; James IE; Marquis RW; Ru Y; Vasko-Moser JA; Smith BR; Tomaszek T; Gowen M
    J Bone Miner Res; 2001 Oct; 16(10):1739-46. PubMed ID: 11585335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K.
    Altmann E; Aichholz R; Betschart C; Buhl T; Green J; Irie O; Teno N; Lattmann R; Tintelnot-Blomley M; Missbach M
    J Med Chem; 2007 Feb; 50(4):591-4. PubMed ID: 17256925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity.
    Falgueyret JP; Desmarais S; Oballa R; Black WC; Cromlish W; Khougaz K; Lamontagne S; Massé F; Riendeau D; Toulmond S; Percival MD
    J Med Chem; 2005 Dec; 48(24):7535-43. PubMed ID: 16302795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors.
    Yamashita DS; Marquis RW; Xie R; Nidamarthy SD; Oh HJ; Jeong JU; Erhard KF; Ward KW; Roethke TJ; Smith BR; Cheng HY; Geng X; Lin F; Offen PH; Wang B; Nevins N; Head MS; Haltiwanger RC; Narducci Sarjeant AA; Liable-Sands LM; Zhao B; Smith WW; Janson CA; Gao E; Tomaszek T; McQueney M; James IE; Gress CJ; Zembryki DL; Lark MW; Veber DF
    J Med Chem; 2006 Mar; 49(5):1597-612. PubMed ID: 16509577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of cathepsin K reduces bone erosion, cartilage degradation and inflammation evoked by collagen-induced arthritis in mice.
    Svelander L; Erlandsson-Harris H; Astner L; Grabowska U; Klareskog L; Lindstrom E; Hewitt E
    Eur J Pharmacol; 2009 Jun; 613(1-3):155-62. PubMed ID: 19358841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K.
    Crane SN; Black WC; Palmer JT; Davis DE; Setti E; Robichaud J; Paquet J; Oballa RM; Bayly CI; McKay DJ; Somoza JR; Chauret N; Seto C; Scheigetz J; Wesolowski G; Massé F; Desmarais S; Ouellet M
    J Med Chem; 2006 Feb; 49(3):1066-79. PubMed ID: 16451072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a nonbasic, nitrile-containing cathepsin K inhibitor (MK-1256) that is efficacious in a monkey model of osteoporosis.
    Robichaud J; Black WC; Thérien M; Paquet J; Oballa RM; Bayly CI; McKay DJ; Wang Q; Isabel E; Léger S; Mellon C; Kimmel DB; Wesolowski G; Percival MD; Massé F; Desmarais S; Falgueyret JP; Crane SN
    J Med Chem; 2008 Oct; 51(20):6410-20. PubMed ID: 18811135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cathepsin K inhibitors increase distal femoral bone mineral density in rapidly growing rabbits.
    Pennypacker BL; Oballa RM; Levesque S; Kimmel DB; Duong LT
    BMC Musculoskelet Disord; 2013 Dec; 14():344. PubMed ID: 24321244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K.
    Barrett DG; Boncek VM; Catalano JG; Deaton DN; Hassell AM; Jurgensen CH; Long ST; McFadyen RB; Miller AB; Miller LR; Payne JA; Ray JA; Samano V; Shewchuk LM; Tavares FX; Wells-Knecht KJ; Willard DH; Wright LL; Zhou HQ
    Bioorg Med Chem Lett; 2005 Aug; 15(15):3540-6. PubMed ID: 15982880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cathepsin K inhibitors: a novel target for osteoporosis therapy.
    Stoch SA; Wagner JA
    Clin Pharmacol Ther; 2008 Jan; 83(1):172-6. PubMed ID: 18073778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1', P1, and/or P3 substitutions.
    Barrett DG; Catalano JG; Deaton DN; Hassell AM; Long ST; Miller AB; Miller LR; Shewchuk LM; Wells-Knecht KJ; Willard DH; Wright LL
    Bioorg Med Chem Lett; 2004 Oct; 14(19):4897-902. PubMed ID: 15341947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent and selective ketoamide-based inhibitors of cysteine protease, cathepsin K.
    Tavares FX; Deaton DN; Miller AB; Miller LR; Wright LL; Zhou HQ
    J Med Chem; 2004 Oct; 47(21):5049-56. PubMed ID: 15456248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo.
    Votta BJ; Levy MA; Badger A; Bradbeer J; Dodds RA; James IE; Thompson S; Bossard MJ; Carr T; Connor JR; Tomaszek TA; Szewczuk L; Drake FH; Veber DF; Gowen M
    J Bone Miner Res; 1997 Sep; 12(9):1396-406. PubMed ID: 9286755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.